Skip to content

Impact of treatment of chronic periodontitis on the serum levels of prohepcidin in patients with chronic kidney disease

Impact of treatment of chronic periodontitis on the serum levels of prohepcidin in patients with chronic kidney disease: Interventional controlled clinical assay

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN59866656
Enrollment
56
Registered
2010-11-18
Start date
2008-08-10
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic periodontitis (CP)

Interventions

Patients with CP were divided into two groups: CKD patients and controls Both groups received instructions on oral hygiene techniques, including the manual techniques of tooth and interproximal brushi

Sponsors

Federal University of Juiz de Fora (Universidade Federal de Juiz de Fora [UFJF]) (Brazil)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients with CP, allocated to one of two groups depending on CKD status 1.1. CKD group: 1.1.1. Patients with CKD at stages 3 to 5 and undergoing conservative treatment 1.1.2. Recruited from the PREVENRIM, a CKD prevention clinic at the Interdisciplinary Nucleus of Studies, Research and Treatment in Nephrology (NIEPEN) of the Universidade Federal de Juiz de Fora (UFJF) 1.2. Control patients: 1.2.1. Patients with no systemic disease from the Periodontology Clinic of the School of Dentistry at UFJF 2. Over 18 years of age, either sex 2. Minimum of 20 natural teeth and without periapical lesions 3. Have received no periodontal, antimicrobial, or anti-inflammatory treatment within the last 6 months 4. Have not used steroids or immunosuppressant drugs within the last 6 months

Exclusion criteria

Exclusion criteria: 1. Pregnant or breast feeding women 2. Smokers or ex-smokers who had quit smoking within the last 10 years

Design outcomes

Primary

MeasureTime frame
Inflammatory markers, assessed at baseline and 3 months post-PT 1. C-reactive protein (us-CRP) 2. Interleukin-6 (IL-6) 3. Prohepcidin

Secondary

MeasureTime frame
Biochemical analyses from blood sample in EDTA, at baseline and 3 months post-PT 1. Complete haemogram (automated Coulter STKS) 2. Serum iron (ferrozine) 3. Ferritin (electrochemiluminescence) 4. Transferrine saturation index (labtest ferrozine)

Countries

Brazil

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 30, 2026